MX338297B - Metodos y composiciones relacionados con fusiones de alk para el diagnostico y tratamiento de cancer. - Google Patents

Metodos y composiciones relacionados con fusiones de alk para el diagnostico y tratamiento de cancer.

Info

Publication number
MX338297B
MX338297B MX2011012162A MX2011012162A MX338297B MX 338297 B MX338297 B MX 338297B MX 2011012162 A MX2011012162 A MX 2011012162A MX 2011012162 A MX2011012162 A MX 2011012162A MX 338297 B MX338297 B MX 338297B
Authority
MX
Mexico
Prior art keywords
fusions
methods
alk
diagnosing
treating cancer
Prior art date
Application number
MX2011012162A
Other languages
English (en)
Other versions
MX2011012162A (es
Inventor
Josh Nickols
Eric Dahlhauser
David Haut
Kim Norman
Original Assignee
Insight Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insight Genetics Inc filed Critical Insight Genetics Inc
Publication of MX2011012162A publication Critical patent/MX2011012162A/es
Publication of MX338297B publication Critical patent/MX338297B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención se refiere a un método para diagnosticar un cáncer relacionado con la fusión de quinasa (ALK) de linfoma anaplásico en un sujeto que comprende llevar a cabo un proceso de amplificación de ácido nucleico en una muestra de tejido del sujeto, en donde el proceso de amplificación de ácido nucleico consiste en detectar la presencia de, o medir la cantidad de ácido nucleico extracelular ALK de tipo silvestre y ácido nucleico de dominio de quinasa de ALK de tipo silvestre en la muestra de tejido y en donde la presencia de, o un incremento de ácido nucleico de dominio de quinasa de ALK de tipo silvestre y la ausencia correspondiente o falta de incremento en la región extracelular ALK de tipo silvestre indica que el sujeto tiene un cáncer relacionado con una fusión de ALK. Un equipo para diagnosticar un cáncer relacionado con una fusión de ALK que comprende (a) un primer cebador que comprende SEQ ID NO: 7, SEQ ID NO: 32, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 57 o SEQ ID NO: 58, etiquetado con un cavador reactivo de detección, en donde el primer cebador es un cebador inverso y (b) por lo menos un segundo cebador, en donde el segundo cebador es un cebador de avance que comprende SEQ ID NO: 6, SEQ ID NO: 45, SEQ ID NO: 48 o SEQ ID NO: 67; y en donde el primer y el segundo cebador hibridan con el dominio de cinasa de ALK de tipo silvestre.
MX2011012162A 2009-05-15 2010-05-17 Metodos y composiciones relacionados con fusiones de alk para el diagnostico y tratamiento de cancer. MX338297B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17893709P 2009-05-15 2009-05-15
PCT/US2010/035147 WO2010132888A2 (en) 2009-05-15 2010-05-17 Methods and compositions relating to fusions of alk for diagnosing and treating cancer

Publications (2)

Publication Number Publication Date
MX2011012162A MX2011012162A (es) 2012-01-30
MX338297B true MX338297B (es) 2016-04-11

Family

ID=43085621

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011012162A MX338297B (es) 2009-05-15 2010-05-17 Metodos y composiciones relacionados con fusiones de alk para el diagnostico y tratamiento de cancer.

Country Status (11)

Country Link
US (2) US20120208713A1 (es)
EP (2) EP3133167B1 (es)
JP (2) JP2012526563A (es)
CN (1) CN102575287B (es)
AU (1) AU2010248782B2 (es)
BR (1) BRPI1012140A2 (es)
CA (1) CA2762108A1 (es)
ES (1) ES2700098T3 (es)
MX (1) MX338297B (es)
RU (1) RU2562144C2 (es)
WO (1) WO2010132888A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3266867A1 (en) 2006-04-14 2018-01-10 Cell Signaling Technology, Inc. Gene defects and mutant alk kinase in human solid tumors
US8168383B2 (en) 2006-04-14 2012-05-01 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
TWI518325B (zh) 2010-02-04 2016-01-21 自治醫科大學 對ａｌｋ抑制劑具有先抗性或後抗性癌症的識別、判斷和治療
US20120101108A1 (en) 2010-08-06 2012-04-26 Cell Signaling Technology, Inc. Anaplastic Lymphoma Kinase In Kidney Cancer
AU2013216904A1 (en) * 2012-02-08 2014-08-28 Insight Genetics, Inc. Methods and compositions relating to fusions of ROS1 for diagnosing and treating cancer
CN102888452B (zh) * 2012-05-18 2014-08-27 复旦大学附属肿瘤医院 一种筛查alk融合基因的方法
US9084456B1 (en) * 2012-05-28 2015-07-21 Jack Zemer Linkage for jewelry components
WO2014026133A1 (en) * 2012-08-09 2014-02-13 Insight Genetics, Inc. Methods and compositions relating to alk for diagnosing and treating inflammatory breast and other human cancers
WO2014036387A2 (en) * 2012-08-31 2014-03-06 The Regents Of The University Of Colorado Methods for diagnosis and treatment of cancer
CN103805687B (zh) * 2012-11-09 2016-06-01 益善生物技术股份有限公司 Alk融合基因检测的pcr引物、试剂盒和液相芯片
RU2509153C1 (ru) * 2012-11-28 2014-03-10 Федеральное государственное бюджетное учреждение "Российский онкологический научный центр имени Н.Н. Блохина" Российской академии медицинских наук (ФГБУ "РОНЦ им. Н.Н. Блохина" РАМН) Способ анализа транслокаций eml4-alk, ассоциированных с чувствительностью рака легкого к противоопухолевой таргетной терапии
CN105378110B (zh) * 2013-04-17 2024-06-25 生命技术公司 与癌症相关的基因融合体和基因变异体
US10072298B2 (en) 2013-04-17 2018-09-11 Life Technologies Corporation Gene fusions and gene variants associated with cancer
CN103290120B (zh) * 2013-05-24 2015-03-25 厦门艾德生物医药科技有限公司 一种用于检测alk基因表达的探针、引物及试剂盒
EP3438288A1 (en) * 2014-03-27 2019-02-06 Life Technologies Corporation Gene fusions and gene variants associated with cancer
US9428812B2 (en) * 2014-04-28 2016-08-30 Insight Genetics, Inc. Kit comprising primers for amplifying ALK kinase domain nucleic acids
WO2016106701A1 (zh) * 2014-12-31 2016-07-07 深圳华大基因股份有限公司 检测非小细胞肺癌的qRT-PCR引物、探针、芯片、试剂盒、应用和方法
US10253349B2 (en) * 2015-04-17 2019-04-09 Roche Molecular Systems, Inc. Multiplex PCR to detect gene fusions
CN107022610B (zh) * 2017-04-01 2019-02-05 常州桐树生物科技有限公司 肿瘤驱动基因的检测芯片及其应用
KR101987065B1 (ko) * 2017-08-07 2019-06-10 주식회사 싸이토젠 Eml4-alk유전자 변이 분석방법
RU2681165C1 (ru) * 2017-12-01 2019-03-04 Общество с ограниченной ответственностью "Научно-Исследовательский Центр Молекулярной Биомедицины" (ООО "НИЦ МолБиоМед") Способ определения активности теломеразы методом двойной амплификации теломерных повторов в реальном времени
CN111235272B (zh) * 2020-01-10 2023-07-07 厦门艾德生物医药科技股份有限公司 一次性检测肺癌多重基因突变的组合物及其应用
CN113005200B (zh) * 2021-04-14 2023-07-04 深圳乐土生物科技有限公司 一种检测肉瘤融合基因突变的引物组合物、试剂盒及应用
CN114807124B (zh) * 2022-04-01 2023-09-12 上海信诺佰世医学检验有限公司 一种检测alk融合基因的引物和探针组合物、试剂盒及方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
DE69433180T2 (de) * 1993-10-26 2004-06-24 Affymetrix, Inc., Santa Clara Felder von nukleinsaeuresonden auf biologischen chips
US6696548B2 (en) * 1993-12-03 2004-02-24 St. Jude Children's Research Hospital Antibodies for recognition of alk protein tyrosine/kinase receptor
US5529925A (en) * 1993-12-03 1996-06-25 St. Jude Children's Research Hospital Nucleic acid sequences and fusion proteins present in human t(2;5) lymphoma
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
GB9812768D0 (en) * 1998-06-13 1998-08-12 Zeneca Ltd Methods
US7339033B2 (en) * 1998-06-26 2008-03-04 Genentech, Inc. Pro1481
GB0319227D0 (en) * 2003-08-15 2003-09-17 Novartis Ag Organic compounds
MX2007008980A (es) * 2005-01-25 2008-01-14 Sky Genetics Inc Acidos nucleicos para apoptosis de celulas cancerigenas.
US8166355B2 (en) * 2005-02-10 2012-04-24 Siano Mobile Silicon Ltd. System and method for mitigating memory requirements
EP1864130A2 (en) * 2005-03-02 2007-12-12 Acadia Pharmaceuticals Inc. Functional bioluminescence energy resonance transfer (bret) assay to screen, identify and characterize receptor tyrosine kinase ligands
US20060286558A1 (en) * 2005-06-15 2006-12-21 Natalia Novoradovskaya Normalization of samples for amplification reactions
CA2598893C (en) * 2006-10-11 2012-04-10 Astellas Pharma Inc. Eml4-alk fusion gene
CN112057625A (zh) * 2007-04-13 2020-12-11 细胞信号技术公司 在人实体瘤中的基因缺损和突变体alk激酶

Also Published As

Publication number Publication date
JP6397833B2 (ja) 2018-09-26
RU2011151049A (ru) 2013-06-20
EP3133167B1 (en) 2018-09-12
JP2012526563A (ja) 2012-11-01
EP3133167A1 (en) 2017-02-22
AU2010248782A1 (en) 2012-01-19
US20170183743A1 (en) 2017-06-29
WO2010132888A2 (en) 2010-11-18
US20120208713A1 (en) 2012-08-16
CA2762108A1 (en) 2010-11-18
ES2700098T3 (es) 2019-02-14
JP2016052332A (ja) 2016-04-14
MX2011012162A (es) 2012-01-30
WO2010132888A3 (en) 2011-01-20
RU2562144C2 (ru) 2015-09-10
CN102575287B (zh) 2016-11-16
BRPI1012140A2 (pt) 2016-05-03
EP2432900A4 (en) 2012-11-21
CN102575287A (zh) 2012-07-11
AU2010248782B2 (en) 2015-06-11
EP2432900A2 (en) 2012-03-28

Similar Documents

Publication Publication Date Title
MX338297B (es) Metodos y composiciones relacionados con fusiones de alk para el diagnostico y tratamiento de cancer.
WO2013119950A3 (en) Methods and compositions relating to fusions of ros1 for diagnosing and treating cancer
WO2009111643A3 (en) Microrna markers for recurrence of colorectal cancer
WO2010001419A3 (en) Copy number variations predictive of risk of schizophrenia
MX2009010439A (es) Variantes geneticas de chr2 y chr16 como marcadores para el uso en valoracion, diagnosis, prognosis y tratamiento de riesgo de cancer de mama.
WO2010129934A3 (en) Methods and compositions for diagnosis of thyroid conditions
WO2009037572A3 (en) Biomarker combinations for colorectal cancer
WO2010017515A3 (en) Breast cancer specific markers and methods of use
WO2008157264A3 (en) Combined methods for the detection of chromosomal aneuploidy
MX2013000917A (es) Metodos para detectar las enfermedades o condiciones usando celulas fagociticas.
MX2014000116A (es) Metodos y acidos nucleicos para determinar el pronostico de un sujeto con cancer.
MX2011009568A (es) Inhibidores de la rho cinasa.
GB201015765D0 (en) Use of myeloid cell biomarkers for the diagnosis of cancer
WO2008089397A3 (en) Adrb2 cancer markers
GB2467467C (en) TAZ/WWTR1 for diagnosis and treatment of cancer
EA200901074A1 (ru) Лечение метастатической стадии рака предстательной железы дегареликсом
IL233548A0 (en) Methods and nucleic acids for the diagnosis of disorders in the development of cells
EP2274437A4 (en) COMPOSITIONS AND METHODS FOR DETECTION OF EGFR MUTATIONS IN CASES OF CANCER
WO2012017430A3 (en) Microrna patterns for the diagnosis, prognosis and treatment of melanoma
WO2008125633A3 (en) Egfr inhibitors for treatment and diagnosis of metastatic prostate cancer
EP2135064A4 (en) AMPEROMETRIC BIOSENSOR FOR THE DETERMINATION OF HISTAMINE
MX2010005060A (es) Identificacion y mapeo a base de microarreglos de adn de puntos de ruptura de translocacion equilibrados.
WO2010007083A3 (en) Methods and nucleic acids for analyses of cell proliferative disorders
MX2009004382A (es) Variaciones geneticas asociadas con tumores.
WO2010037042A3 (en) Methods for detecting and treating cancer

Legal Events

Date Code Title Description
FG Grant or registration